Risk of coronary artery disease in patients with systemic sclerosis: a systematic review and meta-analysis

Abstract

Several chronic inflammatory disorders, such as rheumatoid arthritis and systemic lupus erythematosus, have been shown to increase coronary artery disease (CAD) risk but the data on systemic sclerosis (SSc) is unclear. We conducted a systematic review and meta-analysis of observational studies that reported odds ratio, relative risk, hazard ratio, or standardized incidence ratio comparing CAD risk in patients with SSc versus non-SSc participants. Pooled risk ratio and 95 % confidence intervals were calculated using a random effect, generic inverse variance method. Four studies were identified and included in our data analysis. The pooled risk ratio of CAD in patients with SSc was 1.82 (95 % CI, 1.40 to 2.36). The statistical heterogeneity of this meta-analysis was moderate with an I (2) of 73 %. Our study demonstrated a statistically significant increased CAD risk among patients with SSc.

Risk of ischemic stroke in patients with systemic sclerosis: A systematic review and meta-analysis

“…Subsequent epidemiological studies and a meta-analysis have confirmed this association with an overall 82% excess risk compared with sex and agedmatch controls [14][15][16].…”

The Assessment of Tp-e Interval and Tp-e/QT Ratio in Patients With Systemic Sclerosis

“…There are some studies investigating the association between SSc, coronary fibrosis, and atherosclerosis. [18][19][20] Microvascular dysfunction and fibrosis has a major role in the pathogenesis of the SSc, especially in cardiac complications. 2,3 Myocardial fibrosis is characteristic for heart involvement in SSc and observed in 50% to 70% of patients.…”

Treatment of rapidly progressive systemic sclerosis: current and futures perspectives

“…On the other hand, SSc-associated pulmonary involvement, either interstitial lung disease (ILD) or pulmonary arterial hypertension (PAH), has recently emerged as the leading cause of SSc mortality [31]. Furthermore, the occurrence of a high rate of cardiovascular events in SSc patients has been identified suggesting evidence of both large vessel and small vessel vasculopathy [32–35]. Despite substantial advances in the overall treatment of SSc and the notable increase in SSc survival accomplished recently, currently, there are no approved disease-modifying therapeutic interventions for SSc and there are no drugs that have been shown to reverse SSc-associated ILD.…”